Kyverna Therapeutics, Inc. Board of Directors

Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.

Dr. Dominic Borie M.D., Ph.D.

Dr. Dominic Borie M.D., Ph.D.

President of Research & Development

Ms. Cara Bauer

Ms. Cara Bauer

Chief Human Resources Officer

Ms. Tracy Rossin

Ms. Tracy Rossin

Senior Vice President of Corporate Affairs & Communications and Investor Relations

Mr. Devin Murray

Mr. Devin Murray

Senior Vice President of Partnerships & Alliances

Ms. Karen Walker

Ms. Karen Walker

Chief Technology Officer

Dr. Tom Van Blarcom Ph.D.

Dr. Tom Van Blarcom Ph.D.

Senior VP & Head of Research

Mr. Ryan Jones M.B.A.

Mr. Ryan Jones M.B.A.

Chief Financial Officer

Mr. Dan Maziasz

Mr. Dan Maziasz

Chief Business Officer

Dr. Naji Gehchan M.B.A., M.D.

Dr. Naji Gehchan M.B.A., M.D.

Chief Medical & Development Officer

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.